We investigated the antitumor effect of Cordyceps militaris extract (CME) on A549 cisplatin-resistant (CR) lung cancer cells. The proliferation of A549/CR cells was suppressed by CME. Apoptosis of the cells was induced by CME. The cell cycle arrest was observed in the sub-G1 phase in the cells treated with CME. Proteomic profile analysis showed that H-Ras was downregulated in CME-treated cells and it was confirmed by western blot analysis. Collectively, these data demonstrated that CME is an alternative treatment for the anticancer effect.
Get full access to this article
View all access options for this article.
References
1.
TorreLA, BrayF, SiegeRL, et al.: Global cancer statistics, 2012. CA Cancer J Clin, 2015; 65:87–108.
2.
JungKW, WonYJ, KongHJ, et al.: Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat, 2015; 47:127–141.
3.
SocinskiMA, EvansT, GettingerS, et al.: Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 2013; 143:e341S–e368S.
4.
SiegelRL, MillerKD, JemalA: Cancer statistics, 2015. CA Cancer J Clin, 2015; 65:5–29.
5.
ArdizzoniA, BoniL, TiseoM, et al.: Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis. J Natl Cancer Inst, 2007; 99:847–857.
6.
D'AddarioG, PintilieM, LeighNB, et al.: Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: A meta-analysis of the published literature. J Clin Oncol, 2005; 23:2926–2936.
7.
SchillerJH, HarringtonD, BelaniCP, LangerC, SandlerA, KrookJ, et al.: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 2002; 346:92–98.
8.
HeskethPJ: Chemotherapy-induced nausea and vomiting. N Engl J Med, 2008; 358:2482–2494.
9.
JeongMH, ParkYS, JeongDH, et al.: In vitro evaluation of Cordyceps militaris as a potential radioprotective agent. Int J Mol Med, 2014; 34:1349–1357.
10.
HoribeS, MatsudaA, TanahashiT, et al.: Cisplatin resistance in human lung cancer cells is linked with dysregulation of cell cycle associated proteins. Life Sci, 2015; 124:31–40.
11.
DasSK, MasudaM, SakuraiA, et al.: Medicinal uses of the mushroom Cordyceps militaris: Current state and prospects. Fitoterapia, 2010; 81:961–968.
12.
YueK, YeM, ZhouZ, et al.: The genus Cordyceps: A chemical and pharmacological review. J Pharm Pharmacol, 2013; 65:474–493.
13.
TuliHS, SharmaAK, SandhuSS, et al.: Cordycepin: A bioactive metabolite with therapeutic potential. Life Sci, 2013; 93:863–869.
14.
TianX, LiY, ShenY, et al.: Apoptosis and inhibition of proliferation of cancer cells induced by cordycepin. Oncol Lett, 2015; 10:595–599.
15.
LiaoY, LingJ, ZhangG, et al.: Cordycepin induces cell cycle arrest and apoptosis by inducing DNA damage and up-regulation of p53 in Leukemia cells. Cell Cycle, 2015; 14:761–771.
16.
WangZ, WuX, LiangYN, et al.: Cordycepin induces apoptosis and inhibits proliferation of human lung cancer cell line H1975 via inhibiting the phosphorylation of EGFR. Molecules, 2016; 21:1267.
17.
TaoX, NingY, ZhaoX, et al.: The effects of cordycepin on the cell proliferation, migration and apoptosis in human lung cancer cell lines A549 and NCI-H460. J Pharm Pharmacol, 2016; 68:901–911.
18.
ZhangC, ZhongQ, ZhangXF, et al.: Effects of cordycepin on proliferation, apoptosis and NF-κB signaling pathway in A549 cells. Zhong Yao Cai, 2015; 38:786–789.
19.
NakamuraK, KonohaK, YoshikawaN, et al.: Effect of cordycepin (3'-deoxyadenosine) on hematogenic lung metastatic model mice. In Vivo, 2005; 19:137–141.
20.
HwangJH, JooJC, KimDJ, et al.: Cordycepin promotes apoptosis by modulating the ERK-JNK signaling pathway via DUSP5 in renal cancer cells. Am J Cancer Res, 2016; 6:1758–1771.
21.
ShaoLW, HuangLH, YanS, et al.: Cordycepin induces apoptosis in human liver cancer HepG2 cells through extrinsic and intrinsic signaling pathways. Oncol Lett, 2016; 12:995–1000.
22.
LeeHH, ParkC, JeongJW, et al.: Apoptosis induction of human prostate carcinoma cells by cordycepin through reactive oxygen species-mediated mitochondrial death pathway. Int J Oncol, 2013; 42:1036–1044.
23.
KodamaEN, McCaffreyRP, YusaK, et al.: Antileukemic activity and mechanism of action of cordycepin against terminal deoxynucleotidyl transferase-positive (TdT+) leukemic cells. Biochem Pharmacol, 2000; 59:273–281.
24.
BizarroA, FerreiraIC, SokovićM, et al.: Cordyceps militaris (L.) link fruiting body reduces the growth of a non-small cell lung cancer cell line by increasing cellular levels of p53 and p21. Molecules, 2015; 20:13927–13940.
25.
WenX, LinZQ, LiuB, et al.: Caspase-mediated programmed cell death pathways as potential therapeutic targets in cancer. Cell Prolif, 2012; 45:217–224.
26.
MengF, CaoB, FengZ, et al.: Knockdown of mutated H-Ras V12 expression induces chemosensitivity of hepatocellular carcinoma cells to cisplatin treatment in vitro and in nude mouse xenografts. Oncol Rep, 2014; 32:2023–2030.
27.
LiuL, LingX, TangH, et al.: Poly(ADP-ribosyl)ation enhances H-RAS protein stability and causes abnormal cell cycle progression in human TK6 lymphoblastoid cells treated with hydroquinone. Chem Biol Interact, 2015; 238:1–8.
28.
AdjeiAA: Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst, 2001; 93:1062–1074.
29.
ChangF, LeeJT, NavolanicPM, et al.: Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: A target for cancer chemotherapy. Leukemia, 2003; 17:590–603.
30.
ChoSH, KangIC: The inhibitory effect of cordycepin on the proliferation of cisplatin-resistant A549 lung cancer cells. Biochem Biophys Res Comm, 2018; 498:431–436.
31.
McCubreyJA, SteelmanLS, ChappellWH, et al.: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta, 2007; 1773:1263–1284.
32.
DolcetX, LlobetD, PallaresJ, et al.: NF-kB in development and progression of human cancer. Virchows Arch, 2005; 446:475–482.
33.
ChenJJ, BozzaWP, DiX, et al.: H-Ras regulation of TRAIL death receptor mediated apoptosis. Oncotarget, 2014; 5:5125–5137.
34.
WuYL, ZhouC, HuCP, et al.: Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): An open-label, randomised phase 3 trial. Lancet Oncol, 2014; 15:213–222.
35.
GaoY, FergusonDO, XieW, et al.: Interplay of p53 and DNA-repair protein XRCC4 in tumorigenesis, genomic stability and development. Nature, 2000; 404:897–900.
36.
HayashiJ, SakataKI, SomeyaM, et al.: Analysis and results of Ku and XRCC4 expression in hypopharyngeal cancer tissues treated with chemoradiotherapy. Oncol Lett, 2012; 4:151–155.
37.
DeyoungMP, EllisenLW: p63 and p73 in human cancer: Defining the network. Oncogene, 2007; 26:5169–5183.
38.
IrwinMS, KondoK, MarinMC, et al.: Chemosensitivity linked to p73 function. Cancer Cell, 2003; 3:403–410.
39.
WangHQ, JinJJ, WangJ: Matrine induces mitochondrial apoptosis in cisplatin-resistant non small cell lung cancer cells via suppression of β-catenin/survivin signaling. Oncol Rep, 2015; 33:2561–2566.
